Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
暂无分享,去创建一个
George Sgouros | Jason A Koutcher | Pat B Zanzonico | Steven M Larson | S. Larson | J. Koutcher | P. Zanzonico | G. Sgouros | K. Kolbert | S. Palm | Stig Palm | Richard M. Enmon | Katherine S Kolbert | Richard M Enmon | Cornelia Matei | Su Xu | Ronald L Finn | R. Finn | C. Matei | R. Enmon | Su Xu
[1] C. Waldherr,et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] J. Chatal,et al. Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres. , 1994, Physics in medicine and biology.
[3] J A Parker,et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2001, Critical reviews in oncology/hematology.
[4] J. Samet,et al. Food and Drug Administration , 2007, BMJ : British Medical Journal.
[5] B. Leyland-Jones. Trastuzumab: hopes and realities. , 2002, The Lancet. Oncology.
[6] R. Freedman,et al. Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis. , 2000, Cancer biotherapy & radiopharmaceuticals.
[7] S. Larson,et al. Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] F. Hirsch,et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] George Sgouros,et al. Murine S factors for liver, spleen, and kidney. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] M. Brechbiel,et al. A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin. , 2002, Nuclear medicine and biology.
[11] A. Scott,et al. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. , 2000, Cancer research.
[12] R. Herbst,et al. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. , 2002, Lung cancer.
[13] J. Gutterman,et al. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. , 1996, Oncogene.
[14] D. Scheinberg,et al. Tumor Therapy with Targeted Atomic Nanogenerators , 2001, Science.
[15] D. Goldenberg. Targeted therapy of cancer with radiolabeled antibodies. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] S. Larson,et al. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. , 2001, Cancer research.
[17] Herbert Malamud,et al. MIRD Primer for Absorbed Dose Calculations , 1989 .
[18] F. Orsi,et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide , 2001, European Journal of Nuclear Medicine.
[19] M. J. Mattes,et al. Radionuclide‐antibody conjugates for single‐cell cytotoxicity , 2002, Cancer.
[20] D. Ballon,et al. In vivo multiple‐mouse imaging at 1.5 T , 2003, Magnetic resonance in medicine.
[21] J. Humm,et al. PET Imaging of 86Y-Labeled Anti-Lewis Y Monoclonal Antibodies in a Nude Mouse Model: Comparison Between 86Y and 111In Radiolabels , 2001 .
[22] S. Larson,et al. Imaging transgene expression with radionuclide imaging technologies. , 2000, Neoplasia.
[23] G Sgouros,et al. Implementation and evaluation of patient-specific three-dimensional internal dosimetry. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] D. Scheinberg,et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] S. Nightingale,et al. From the Food and Drug administration. , 1990, JAMA.
[26] S. Larson,et al. Low energy cyclotron production and separation of yttrium-86 for evaluation of monoclonal antibody pharmacokinetics and dosimetry , 1999 .
[27] C. Kotts,et al. 186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts. , 1996, Cancer biotherapy & radiopharmaceuticals.
[28] D. Scheinberg,et al. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. , 1995, Nuclear medicine and biology.
[29] S. Denardo,et al. Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies. , 2001, Critical reviews in oncology/hematology.
[30] L. Gordon,et al. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. , 2002, Seminars in oncology.
[31] J Humm,et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[32] R. Wahl,et al. Choosing an optimal radioimmunotherapy dose for clinical response , 2002, Cancer.
[33] L. Norton,et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.